A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Tranquility
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 07 Mar 2018 According to an Esperion Therapeutics media release, the company plans to present full results from this study at a medical conference and to publish in a major medical journal
    • 07 Mar 2018 Primary endpoint has been met (Percent change in low-density lipoprotein cholesterol (LDL-C)), as reported in an Esperion Therapeutics media release.
    • 07 Mar 2018 Results presented in an Esperion Therapeutics media release Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top